Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Curatis Holding AGXSWX:CURN +10.50%33 EV-to-OCF is -78.63 as of Aug. 18, 2026. GuruFocus rates XSWX:CURN with a GF Score™ of 33/100. The stock has 4 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Curatis Holding AG ranks better than 95.02% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Curatis Holding AG's Enterprise Value is CHF103.01 Mil.
Curatis Holding AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-1.31 Mil. Therefore, Curatis Holding AG's EV-to-OCF for today is -78.63.
The historical rank and industry rank for Curatis Holding AG's EV-to-OCF or its related term are showing as below:
XSWX:CURN'
s EV-to-OCF Range Over the Past 10 Years
Min: -93.77 Med: -42.2 Max: -30.91
Current: -70.54
During the past 5 years, the highest EV-to-OCF of Curatis Holding AG was -30.91. The lowest was -93.77. And the median was -42.20.
XSWX:CURN's EV-to-OCF is ranked better than 95.02% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 11
vs XSWX:CURN: -70.54
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Curatis Holding AG (XSWX:CURN) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Curatis Holding AG's PE Ratio (TTM) for today is calculated as:
Curatis Holding AG's share price for today is CHF20.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Curatis Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-0.284.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Curatis Holding AG EV-to-OCF Related Terms
Curatis Holding AG EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Curatis Holding AG's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:CURN vs ZTS, UTHR, VTRS: EV-to-OCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Curatis Holding AG's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Curatis Holding AG EV-to-OCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Curatis Holding AG's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Curatis Holding AG's EV-to-OCF falls into.
Curatis Holding AG's current Enterprise Value is CHF103.01 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Curatis Holding AG's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was CHF-1.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Curatis Holding AG (XSWX:CURN) has a EV-to-OCF of -78.63 as of Aug. 18, 2026. According to the industry distribution chart, Curatis Holding AG ranks #50 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 5%.
Is Curatis Holding AG's EV-to-OCF too high?
Curatis Holding AG's current EV-to-OCF is -78.63. Based on the distribution chart, Curatis Holding AG ranks #50 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Curatis Holding AG has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Curatis Holding AG's EV-to-OCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Curatis Holding AG ranks #50 out of 1005 companies for EV-to-OCF. This places Curatis Holding AG in the top 5% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 11.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 11.00, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 11.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Curatis Holding AG's current EV-to-OCF is -78.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curatis Holding AG stock overvalued right now?
Curatis Holding AG (XSWX:CURN) has a current EV-to-OCF of -78.63. The current EV-to-OCF is -78.63. Curatis Holding AG's overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Curatis Holding AG (XSWX:CURN), the current EV-to-OCF is -78.63 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Curatis Holding AG is a specialty pharmaceutical Company with two-pillar. On one hand, the Company trades and distributes specialty medicines in the rare disease and specialty medicines space i.e. acquires, licenses, distributes and promotes pharmaceutical products for the treatment and/or prevention of rare and specialty diseases in Switzerland. On the other hand, it is a drug development Company with a pipeline of product candidates, also predominantly in the orphan drug space.
33GF Score
Get the complete analysis for XSWX:CURN
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:CURN has been successfully added to your 
